Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues.
The silylated amino acid (l)-(trimethylsilyl)alanine (TMSAla) was incorporated at the C-terminal end of the minimal biologically active neurotensin (NT) fragment, leading to the synthesis of new hexapeptide NT[8-13] analogues. Here, we assessed the ability of these new silylated NT compounds to bind to NTS1 and NTS2 receptors, promote regulation of multiple signaling pathways, induce inhibition of the ileal smooth muscle contractions, and affect distinct physiological variables, including blood pressure and pain sensation. Among the C-terminal modified analogues, compound 6 (JMV2007) carrying a TMSAla residue in position 13 exhibits a higher affinity toward NT receptors than the NT native peptide. We also found that compound 6 is effective in reversing carbachol-induced contraction in the isolated strip preparation assay and at inducing a drop in blood pressure. Finally, compound 6 produces potent analgesia in experimental models of acute and persistent pain.
Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France.
Roberto
R
Fanelli
Department of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke, Faculty of Medicine and Health Sciences, Université de Sherbrooke , Sherbrooke, Québec J1K 2R1, Canada.
Élie
É
Besserer-Offroy
Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France.
Adeline
A
René
Department of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke, Faculty of Medicine and Health Sciences, Université de Sherbrooke , Sherbrooke, Québec J1K 2R1, Canada.
Jérôme
J
Côté
Department of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke, Faculty of Medicine and Health Sciences, Université de Sherbrooke , Sherbrooke, Québec J1K 2R1, Canada.
Pascal
P
Tétreault
Department of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke, Faculty of Medicine and Health Sciences, Université de Sherbrooke , Sherbrooke, Québec J1K 2R1, Canada.
Jasmin
J
Collerette-Tremblay
Department of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke, Faculty of Medicine and Health Sciences, Université de Sherbrooke , Sherbrooke, Québec J1K 2R1, Canada.
Jean-Michel
JM
Longpré
Department of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke, Faculty of Medicine and Health Sciences, Université de Sherbrooke , Sherbrooke, Québec J1K 2R1, Canada.
Richard
R
Leduc
Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France.
Jean
J
Martinez
Department of Pharmacology and Physiology, Institut de Pharmacologie de Sherbrooke, Faculty of Medicine and Health Sciences, Université de Sherbrooke , Sherbrooke, Québec J1K 2R1, Canada.
Philippe
P
Sarret
Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université Montpellier, ENSCM, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France.
Florine
F
Cavelier
D000700:Analgesics / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive; D001794:Blood Pressure / Q000187:drug effects; D016466:CHO Cells; D060326:Chemistry Techniques, Synthetic; D003412:Cricetulus; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006207:Half-Life; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects; D009496:Neurotensin / Q000031:analogs & derivatives* / Q000737:chemistry*; D017207:Rats, Sprague-Dawley; D018028:Receptors, Neurotensin / Q000235:genetics / Q000378:metabolism
D000700:Analgesics; D018028:Receptors, Neurotensin; C114036:neurotensin type 1 receptor; D009496:Neurotensin